The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFFWD.L Regulatory News (FFWD)

  • There is currently no data for FFWD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Investee Company Update: Nuuvera Inc.

23 Mar 2018 15:35

RNS Number : 8171I
FastForward Innovations Limited
23 March 2018
 

 

23 March 2018

 

FastForward Innovations Limited

("FastForward"")

Investee Company Update: NUUVERA INC.

COMPLETION OF PLAN OF ARRANGEMENT WITH APHIRA INC.

FastForward notes the announcement today by investee company Nuuvera Inc. ("Nuuvera" (TSXV: NUU)), a public company formed to capitalize on the global trend towards the legalisation of medical cannabis, in which FastForward currently has a holding of 3 million shares or 3.4%. The announcement is set out below without material changes or adjustments:

LEAMINGTON and TORONTO, ON , March 23, 2018 /CNW/ - Aphria Inc. ("Aphria") (TSX:APH and US OTC: APHQF) and Nuuvera Inc. ("Nuuvera") (NUU.V) are pleased to announce that they have completed the previously announced arrangement (the "Arrangement") under the provisions of the Business Corporations Act ( Ontario ), pursuant to which, among other things, Aphria has acquired all of the common shares of Nuuvera (the "Nuuvera Shares") not already owned by it.

Under the terms of the Arrangement, each former Nuuvera shareholder is now entitled to receive $0.62 in cash, rather than $0.60 , as previously announced, plus 0.3546 of a common share of Aphria, for each Nuuvera Share held prior to the Arrangement (the "Consideration"). The increase in the cash consideration is a result of Nuuvera's cash on hand exceeding the Restricted Cash Amount (as defined in the Arrangement Agreement Amending Agreement dated February 19 , 2018). 

It is anticipated that the Nuuvera Shares will be delisted from the TSX Venture Exchange as of the close of trading on or about March 26, 2018 and Nuuvera intends to submit an application to the applicable securities regulators to cease to be a reporting issuer and to terminate its public reporting obligations.

Pursuant to the letter of transmittal mailed to Nuuvera shareholders as part of the material in connection with the special meeting of Nuuvera shareholders held on March 20, 2018 (the "Meeting"), in order to receive the Consideration to which they are entitled, registered holders of Nuuvera Shares will be required to deposit their share certificate(s) representing Nuuvera Shares, together with the duly completed letter of transmittal, with TSX Trust Company, the depositary under the Arrangement. Shareholders whose Nuuvera Shares are registered in the name of a broker, dealer, bank, trust company or other nominee should contact their nominee with questions regarding the receipt of the Consideration.

Further information about the Arrangement is set forth in the materials prepared by Nuuvera in respect of the Meeting which were mailed to Nuuvera shareholders and filed under Nuuvera's profile on the System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com.

About Aphria

Aphria, one of Canada's lowest-cost medical cannabis producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario , the greenhouse capital of Canada , Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. Aphria is committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders.

For more information about Aphria, please visit www.aphria.ca

About Nuuvera

Nuuvera is a global cannabis company founded on Canadian principles, and built with the whole world in mind. Nuuvera is currently working with partners in Germany , Israel and Italy , and is exploring opportunities in several other countries, to develop commercial production and global distribution of medical grade cannabis in legalized markets. Through its subsidiaries, ARA - Avanti and Avalon Pharmaceutical Inc., Nuuvera holds a Dealer License (GMP) under the Narcotic Control Regulations and Office of Controlled Substances. Nuuvera is currently in the final stages of the Health Canada review process to become a Licensed Producer of medical marijuana under the ACMPR, and has recently received its "letter to build" approval.

For more information about Nuuvera, please visit: www.nuuvera.com

 

CONTACTS:

 

FastForward Innovations Limited info@fstfwd.co

Ed McDermott/ Sue Saunders/ Ian Burns

Beaumont Cornish Limited (Nomad) Tel: +44 (0) 207 628 3396

James Biddle / Roland Cornish

Optiva Securities Limited (Broker) Tel: +44 (0) 203 411 1881

Graham Dickson

CAUTIONARY STATEMENT

The AIM Market of London Stock Exchange plc does not accept responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of FastForward Innovations Ltd. There can be no assurance that such statements will prove to be accurate, achievable or recognizable in the near term.

Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. FastForward Innovations assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBUGDXSXDBGIX
Date   Source Headline
25th Feb 20207:00 amRNSInvestee Company Update: EMMAC Life Sciences
18th Feb 20207:00 amRNSInvestee Company Update: EMMAC Life Sciences
11th Feb 20207:00 amRNSUpdated Key Information Document
31st Jan 20201:30 pmRNSInvestee Company Update: Portage Biotech Inc.
8th Jan 20207:00 amRNSDisposal of Interest in Cryptologic Corp
7th Jan 20207:00 amRNSBoard Appointment
3rd Jan 20201:15 pmRNSInvestee Company Update: Portage Biotech Inc.
11th Dec 20197:00 amRNSHalf-year Report
5th Dec 20192:45 pmRNSTR-1 Notification
19th Nov 20197:00 amRNSLorne Abony appointed as Chairman of EMMAC
16th Oct 20197:00 amRNSInvestee Company Update: EMMAC Life Sciences
15th Oct 20197:00 amRNSInvestee Company Update: Factom inc.
10th Oct 20199:25 amRNSResult of 2019 AGM
27th Sep 20194:31 pmRNSDirector Dealing in the Company
27th Sep 20197:00 amRNSInvestee Company Update : Fralis LLC (Leap Gaming)
26th Sep 201911:21 amRNSInvestee Company Update : Cryptologic Corp
16th Sep 201911:52 amRNSTR-1 Notification of major holdings
11th Sep 20198:00 amRNSResults for the year ended 31st March 2019
11th Sep 20198:00 amRNSNotice of 2019 Annual General Meeting
22nd Aug 201912:01 pmRNSDirectorate Change
19th Aug 20199:23 amRNSJuvenescence closes Series B funding
12th Aug 20193:02 pmRNSInvestee Company Update-Cryptologic issues loan
12th Aug 201910:11 amRNSPortage Trading Suspended
6th Aug 20194:42 pmRNSInvestee Company Update: Cryptologic Corp
30th Jul 201911:07 amRNSSAFE Agreement with Factom, Inc. Extended
25th Jul 20198:17 amRNSFactom Inc SAFE Agreement temporary extension
18th Jul 201911:20 amRNSInvestee Company Update: Regent Pacific on Yooya
16th Jul 20199:13 amRNSInvestee Company Update:EMMAC acquires Terre Verde
11th Jul 20193:00 pmRNSDisposal of interest in Intensity Therapeutics Inc
9th Jul 201910:51 amRNSInvestee Company Update: EMMAC enters new Market
26th Jun 20198:56 amRNSInvestee Company Update: Intensity Therapeutics
29th May 20193:43 pmRNSInvestee Company Update: Offer for Yooya
13th May 201910:21 amRNSDisposal of interest in Vemo Education Inc.
18th Apr 20197:00 amRNSInvestee Company Update: Intensity Therapeutics
4th Apr 20199:51 amRNSTR1 - Correction
3rd Apr 20194:00 pmRNSTR:1 Regent Mercantile Holdings Limited
20th Mar 201911:00 amRNSCompletion of £2 million investment in EMMAC
7th Mar 20194:03 pmRNS£2 million investment in EMMAC Life Sciences
15th Jan 20193:45 pmRNSJuvenescence Series B Funding
3rd Jan 201911:47 amRNSBoard Appointment
12th Dec 201812:52 pmRNSHalf-year Report
3rd Dec 20187:00 amRNSInvestee Company Update: Factom and Yooya
14th Nov 20181:31 pmRNSInvestee Company Update: Factom Inc
22nd Oct 201812:24 pmRNSIntensity Therapeutics Inc Update
12th Sep 20186:12 pmRNSResult of AGM
10th Sep 20189:16 amRNSHolding(s) in Company
22nd Aug 20188:08 amRNSDirector Dealing
3rd Aug 201812:48 pmRNSShareholder update
3rd Aug 20188:00 amRNSPlacing
1st Aug 201812:05 pmRNSResponse to Media Speculation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.